论文部分内容阅读
目的观察曲美他嗪治疗缺血性心脏病心功能不全的临床疗效及安全性。方法选择116例缺血性心脏病心功能不全患者随机分为治疗组60例和对照组成56例。对照组给予正规抗心力衰竭治疗;治疗组在对照组常规治疗基础上加服曲美他嗪20mg,每日3次。2组疗程均为6个月。观察2组治疗前后临床疗效、左室舒张末内径(LVEDD)、左室射血分数(LVEF)、血清B型尿钠肽(BNP)、6min步行试验及药物不良反应等。结果治疗6个月后,治疗组的总有效率93.3%显著高于对照组75.0%(P<0.05);在LVEDD、LVEF、6min步行距离结果及BNP改善的程度等方面,治疗组均优于对照组(P<0.05);治疗组发生药物不良反应少而轻微。结论缺血性心脏病心功能不全患者长期服用曲美他嗪可使心功能改善,安全有效。
Objective To observe the clinical efficacy and safety of trimetazidine in the treatment of cardiac insufficiency of ischemic heart disease. Methods A total of 116 patients with ischemic heart disease and cardiac insufficiency were randomly divided into treatment group (60 cases) and control group (56 cases). The control group was given formal anti-heart failure treatment. The treatment group was given trimetazidine 20 mg on the basis of routine treatment in the control group three times a day. Two groups of treatment were 6 months. The clinical efficacy, left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), serum B-type natriuretic peptide (BNP), 6min walk test and adverse drug reactions were observed before and after treatment. Results After 6 months of treatment, the total effective rate of the treatment group was 93.3%, which was significantly higher than that of the control group (75.0%, P <0.05). In the LVEDD, LVEF, 6min walk distance results and the degree of improvement of BNP, Control group (P <0.05); adverse reactions in the treatment group with less and minor. Conclusion Long-term administration of trimetazidine in patients with ischemic heart disease can improve cardiac function and be safe and effective.